Share this article
Share this article
EXTON, Pa., April 7, 2021 /PRNewswire/ Since late March 2020, Spherix has been surveying specialty physicians (dermatologists, gastroenterologists, nephrologists, neurologists, and rheumatologists) in the United States to track the impact of the COVID-19 pandemic on their practice operations, personal concerns, interaction with the pharmaceutical industry, and outlook for the near term. In all, Spherix collected feedback from more than 4,000 respondents via online survey, and the culmination of the report series,
Special Topix™: Multi-Specialty Impact of COVID-19 (US),
was released last week – highlighting the evolution of the past year s events.
The 16
th wave, which is based on the responses of 267 US specialists surveyed on March 12, 2021, provides a unique year-over-year view of the impact of COVID-19. Here s where things stand today:
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis
News provided by
Share this article
Share this article
EXTON, Pa., Jan. 29, 2021 /PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering,